Business
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
AACR abstracts highlight the Company’s proprietary gene circuit engineered allogeneic CAR-NK cell therapies being developed for hematologic and solid tumors
About this update from Senti Biosciences Holdings, Inc.
[{"type":"text","content":"AACR abstracts highlight the Company’s proprietary gene circuit engineered allogeneic CAR-NK cell therapies being developed for hematologic and solid tumors\nSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the acceptance of three abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida. Senti Bio is using gene circuits to create next-generation cell and gene therapies and is advancing a pipeline of gene circuit-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies. AACR presentation information: Title: Preclinical development of SENTI-202, an off-the-shelf logic gated CAR-NK cell therapy, for the treatment of CD33/FLT3+ hematologic malignancies including AMLAuthors: Alba Gonzalez, Gozde Yucel, Enping Hong, Elizabeth Leitner, Pearley Chinta, Han Deng, Ian Li, Alice Lam, Abla Bakir, Brandon Lee, Papia Chakraborty, Carmina Blanco, Kelly Lee, Niran Almudhfar, Mengxi Tian, Wenqi Song, Andrew Banicki, Otto Contreras, Marty Gieldin, Brian Garrison, Timothy Lu, Kanya RajangamDate and Time: Monday Apr 17, 2023 1:30 PM - 5:00 PMSession Name: Adoptive Cell Therapy 2Abstract Number: 3195 Preclinical data will be presented describing the efficacy and safety profile of SENTI-202, a first-in-class logic gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) while sparing the healthy bone marrow. SENTI-202 is also multi-armed with a calibrated release IL-15 (crIL-15) gene circuit to provide NK cell activation and persistence. These data support the clinical development of SENTI-202 as a novel therapeutic option for patients with CD33+ and/or FLT3+ tumors. Senti Bio plans to file an Investigational New Drug (IND) Application for SENTI-202 in the second half of 2023. Title: Off-the-Shelf CAR-NK cells engineered to express calibrated release IL-15 exhibit enhanced persistence and anti-tumor activitiesAuthors: Chen-Ting Lee, Michelle Hung, Andrew Banicki, Wenqi Song, Niran Almudhf...